High flow nasal cannula: recommendations for daily practice in pediatrics

Annals of Intensive Care 2014, 4:29  doi:10.1186/s13613-014-0029-5

Christophe Milési (c-milesi@chu-montpellier.fr)
Mathilde Boubal (m-boubal@chu-montpellier.fr)
Aurélien Jacquot (a-jacquot@chu-montpellier.fr)
Julien Baleine (j-baleine@chu-montpellier.fr)
Sabine Durand (sabine-durand@chu-montpellier.fr)
Marti Pons Odena (pons.marti@gmail.com)
Gilles Cambonie (g-cambonie@chu-montpellier.fr)

Published online: 30 September 2014

ISSN 2110-5820
Article type Review
Submission date 16 May 2014
Acceptance date 20 August 2014
Article URL http://www.annalsofintensivecare.com/content/4/1/29

This peer-reviewed article can be downloaded, printed and distributed freely for any purposes (see copyright notice below).

For information about publishing your research in Annals of Intensive Care go to http://www.annalsofintensivecare.com/authors/instructions/

For information about other SpringerOpen publications go to http://www.springeropen.com

© Milesi et al.; licensee Springer
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
High-flow nasal cannula: recommendations for daily practice in pediatrics

Christophe Milési\textsuperscript{1,3,*}
Email: c-milesi@chu-montpellier.fr

Mathilde Boubal\textsuperscript{1}
Email: m-boubal@chu-montpellier.fr

Aurélien Jacquot\textsuperscript{1}
Email: a-jacquot@chu-montpellier.fr

Julien Baleine\textsuperscript{1}
Email: jf-baleine@chu-montpellier.fr

Sabine Durand\textsuperscript{1}
Email: sabine-durand@chu-montpellier.fr

Marti Pons Odena\textsuperscript{2}
Email: pons.marti@gmail.com

Gilles Cambonie\textsuperscript{1}
Email: g-cambonie@chu-montpellier.fr

\textsuperscript{1} Département de Pédiatrie Néonatale et Réanimations, Pôle Universitaire Enfant, CHRU de Montpellier, Montpellier 34000, France

\textsuperscript{2} Unidad de Cuidados Intensivos Pediatricos, Hospital Universitario Sant Joan de Deu, Universitat de Barcelona, Esplugues de Llobregat, Barcelona 08950, Spain

\textsuperscript{3} Réanimation Pédiatrique, Hôpital Arnaud de Villeneuve, 371 avenue du doyen G. Giraud, 34295 Montpellier CEDEX 5, France

\textsuperscript{*} Corresponding author. Département de Pédiatrie Néonatale et Réanimations, Pôle Universitaire Enfant, CHRU de Montpellier, Montpellier 34000, France
Abstract

High-flow nasal cannula (HFNC) is a relatively new device for respiratory support. In pediatrics, HFNC use continues to increase as the system is easily set up and is well tolerated by patients. The use of nasal cannula adapted to the infant’s nares size to deliver heated and humidified gas at high flow rates has been associated with improvements in washout of nasopharyngeal dead space, lung mucociliary clearance, and oxygen delivery compared with other oxygen delivery systems. HFNC may also create positive pharyngeal pressure to reduce the work of breathing, which positions the device midway between classical oxygen delivery systems, like the high-concentration face mask and continuous positive airway pressure (CPAP) generators. Currently, most of the studies in the pediatric literature suggest the benefits of HFNC therapy only for moderately severe acute viral bronchiolitis. But, the experience with this device in neonatology and adult intensive care may broaden the pediatric indications to include weaning from invasive ventilation and acute asthma. As for any form of respiratory support, HFNC initiation in patients requires close monitoring, whether it be for pre- or inter-hospital transport or in the emergency department or the pediatric intensive care unit.

Keywords

PICU; High-flow nasal cannula; Bronchiolitis; Asthma

Review

Introduction

Over the last decade, high-flow nasal cannula (HFNC) has increasingly been used for oxygen delivery in neonatology departments, gradually replacing nasal continuous positive airway pressure (CPAP). Its use in pediatrics departments is more recent and generally is restricted to children with moderate bronchiolitis. The cannula was first employed in intensive care units (ICUs), then in emergency departments, and today is finding use during pre- or inter-hospital transport.

Clinicians are quite rightly raising questions about where it should be positioned among the systems of noninvasive respiratory support, such as high-concentration face masks and nasal CPAP. Its mode of action is original and complex. Initiating HFNC is relatively simple, but close monitoring is essential. Since the critical review of HFNC use in ill infants, children, and adults [1], additional physiological and clinical data have been reported, particularly in infants with acute viral bronchiolitis. The range of indications for HFNC is also likely to broaden in the future, and further studies are therefore needed to ensure that the guidelines for use are evidence-based.

Mechanism of action

HFNC is designed to administer a heated and humidified mixture of air and oxygen at a flow higher than the patient’s inspiratory flow [1]. There is currently no single, simple definition of high flow. In infants, it usually refers to the delivery of oxygen or an oxygen/room air
blend at flow rates greater than 2 L/min [2]. Some authors adjust the flow rates on body weight and recommend using 2 L/kg/min, which provides a degree of distending pressure [3-5] and reduces the work of breathing [6]. In children, flow rates >6 L/min are generally considered high flow [1]. High flow presents several advantages over conventional ‘low-flow’ oxygen therapy in terms of humidification, oxygenation, gas exchange, and breathing pattern.

**Gas mixture conditioning**

HFNC provides a relative humidity of nearly 100% with the gas warmed to between 34°C and 37°C. Compared with ‘low-flow oxygenation’ or the high-concentration oxygen mask, HFNC improves patient tolerance by reducing the sensation of respiratory distress and mouth dryness [7]. Moreover, Hasani et al. observed tracer movements and demonstrated improved mucociliary clearance [8]. In comparisons of HFNC and conventional oxygen therapy, this effect is thought to explain the drop in exacerbation episodes and the improved quality of life in adult patients with chronic obstructive pulmonary disease (COPD) [9].

Another benefit of gas conditioning is the improved inspiratory flow, which further increases the feeling of comfort. Heated and humidified gas diminishes the resistance in the nasal mucosa induced by dry and cold gas [10], a point that should not be neglected given that these resistances make up nearly 50% of the total resistance of the respiratory system.

**High flow**

Several studies have shown that a flow higher than the patient’s inspiratory flow provides better oxygen delivery than low-flow oxygen therapy or the high-concentration oxygenation mask. This observation has been explained as the effect of a high flow on the oropharyngeal dead space, with the idea being that the high flow of oxygen ‘washes out’ the end-expiratory oxygen-depleted gas. In the next breath, the patient inhales pure oxygen [7,11,12]. Dead space washout also reduces CO₂ rebreathing.

The extrathoracic dead space is proportionally two to three times greater in children than in adults. It may measure up to 3 mL/kg in newborns and becomes similar to the adult volume only after 6 years of age (0.8 mL/kg) [13]. Consequently, the younger a child is, the greater the effect of a high flow on oxygenation and CO₂ clearance [14].

**Generated pressures**

A high-flow mixture is likely to create a maximum positive pharyngeal pressure of about 6 cm H₂O during expiration [3,15-17]. The pressure is determined not only by the flow, but also by the ratio of the prong/nostril fit and whether or not the mouth is closed. The inter- and intra-individual variations are nevertheless quite wide [18].

In a physiological study of infants with acute viral bronchiolitis, we measured pharyngeal pressure over the course of a gradual increase in flow up to 7 L/min (Figure 1) [3]. When we indexed the flow to patient weight, we observed that the average pressure with a flow of 2 L/kg/min was about 4 cm H₂O. Unfortunately, despite the overall shape of the curve, we could not predict whether a higher flow would provide greater pressure. The pharyngeal pressure at a rate of 1 L/min appeared like a sine wave around the air pressure, being negative during inspiration and positive during expiration (Figure 2). The sinusoidal shape persisted
when we increased the flow, but the two pressure components (inspiratory and expiratory) became positive after 7 L/min, thereby generating real CPAP.

**Figure 1** Pharyngeal pressure (PP) over the course of a gradual increase in flow. The flow is indexed to patient weight ($R = 0.77$, $p < 0.001$). A flow $>2$ L/kg/min is associated with mean pharyngeal pressure $>4$ cm H$_2$O (sensitivity 67%, specificity 96%, positive predictive value 75%, negative predictive value 94.5%). Adapted from Milesi et al. [3].

**Figure 2** Recording of the pharyngeal pressure (PP) at 1 and 7 L/min in an infant.

The pressures generated by the device prevent pharyngeal collapse, which may be very pronounced in some diseases. It reduces obstructive apnea and supports the inspiratory effort when patient flow is limited. In infants with bronchiolitis, Pham et al. recently showed that HFNC reduced the electrical activity of the diaphragm and decreased esophageal pressure swings, confirming the effectiveness of this therapy to reduce the work of breathing [6]. The effects of CPAP differ with the ventilation phase. Positive pressure at the beginning of inspiration may compensate the inspiratory burden related to auto-positive end-expiratory pressure (auto-PEEP) and facilitate inspiratory flow. Positive pressure during expiration prevents small airway collapse (stenting effect), increases the expiratory time and reduces the auto-PEEP.

The favorable effect of this technique on the ventilation/perfusion ratio has not been clearly established. This suggests the need for caution when HFNC is used in the management of respiratory failure type 1. In this case, the ventilation/perfusion mismatch dominates the pathophysiology, whereas alveolar ventilation is relatively preserved [19].

**Reduced energy expenditure**

The burden on the respiratory muscles may be very high in children with obstructive respiratory distress. The high energy expenditure may lead to respiratory muscle failure and recourse to mechanical ventilation. The risk of decompensation is particularly high in young infants because their respiratory muscles are poorly equipped with oxidative fibers, which increases muscle vulnerability to excessive and prolonged work.

Several features of HFNC suggest positive effects on energy expenditure compared with conventional oxygen therapy, notably preserved mucociliary function, prevention of atelectasis, and decreased inspiratory work [3,6,8-10,14-20].

**Side effects and monitoring**

HFNC stands out from conventional oxygen therapy because it provides a heated and humidified air flow that counteracts the unpleasant sensation of a dry mouth [7]. This nuisance is one of the major sources of discomfort cited by ICU patients. Compared with other systems delivering CPAP, cutaneous tolerance is better with fewer skin lesions reported [21]. However, like any respiratory support system, this device has drawbacks. For example, the noise level reaches about 80 dB. The decibel level is correlated with the flow and may be higher than that generated by other CPAP systems [22].

Recently, three episodes of pneumothorax and pneumodiastinum were reported during HFNC use [23]. The risk of air leak syndrome could be associated with an inappropriate prong size.
that occludes the nostril lumen [24]. Another difficulty with this device as a substitute for CPAP is the great intra- and inter-patient variation in the pressures generated in the airways [18]. Flow rates may be titrated to the evolving status of respiratory distress, but the safety of this practice is uncertain because subsequent changes in generated pressure are not measured.

Finally, the greatest risk in using HFNC, as for any noninvasive ventilation (NIV) strategy, is that recourse to more invasive management may be delayed in cases of respiratory decompensation. Some authors have thus suggested that the failure of NIV, because it delays the recourse to mechanical ventilation, may actually increase mortality/morbidity. Up to now, this observation has been confined to the adult population [25]. In children, the risk of HFNC failure, defined as intubation requirement, ranges from 8% to 19% [15,26-29] and reaches nearly 30% when escalation in respiratory support is also taken into consideration [4]. In children younger than 2 years, HFNC failure may occur within 7 to 14 h [28,29], whereas with other NIV strategies, failure was usually observed in the first 2 h following initiation [30]. In the absence of randomized controlled trials, it is impossible to determine whether this difference is due to the characteristics of the population, the variability in disease progression, or the respiratory support itself. HFNC should therefore be initiated in an emergency department or a pediatric ICU that has sufficient staff to closely monitor the patient’s clinical course and that is well trained to recognize the early signs of failure. After several hours of stability, the infant may be transferred to a conventional ward, depending on hospital policy.

HFNC initiation in practice (Figure 3)

**Figure 3 HFNC initiation and monitoring.** PED, pediatric emergency department; PICU, pediatric intensive care unit; RR, respiratory rate; HR, heart rate; NIV, noninvasive ventilation.

The HFNC system has few parts: the cannula, a flow generator, an air/oxygen blender, and a respiratory gas humidifier.

Where to initiate HFNC

Although most studies of HFNC therapy have focused on ICUs, recent works have shown that HFNC can be used to manage moderate respiratory distress in emergency departments [29] and during pre- or inter-hospital transport [31]. One of the advantages of HFNC is that it requires minimal technical skill to set up and apply. Nevertheless, initiating this type of respiratory support requires advanced experience in managing acute pediatric respiratory illness, adequate technical monitoring and a high staff/patient ratio. The risk of decompensation requires very close monitoring in a setting that is equipped for rapid implementation of invasive ventilatory support. Discharge from the ICU and transfer to a pediatric ward can be considered only once the continued improvement of these children is well underway. The ward admitting the child will nevertheless need to provide close surveillance and be equipped with a centralized alarm system for early detection of respiratory failure or signs of decompensation.
**Cannula**

The prong caliber is adapted to the nostril size in order to allow for leakage and avoid overpressure phenomena. The prong diameter should be about half that of the nostril [24]. It may be useful for infants to reduce mouth leaks with a pacifier.

**Generator**

Three types of gas generators are currently available:

- The first type uses an air/oxygen blender and is connected to a system to humidify and heat the gas. Several devices are available: Optiflow System® (Fisher and Packel, Auckland, New Zealand), Precision Flow® (Vapotherm, Exeter, UK), and Comfort-Flo® (Teleflex Medical, Durham, NC, USA). There may be a pressure relief valve that cuts off the flow when a predetermined pressure in the circuit is reached. The practical consequence of this valve is flow limitation depending on the cannula size.
- The second type uses a turbine + humidifier (Airvo2®, Fisher and Packel, Auckland, New Zealand). This system has the advantage of not requiring an external source of gas, except oxygen. This device cannot be used with neonates and its start-up is sometimes a bit long compared with other types.
- The third type is based on a CPAP or conventional ventilator with an HFNC breathing circuit connected to the humidifier.

**Settings**

In infants, flow rates are greater than 2 L/min [2] and may be adjusted to body weight, i.e., 2 L/kg/min [3-6]. In children, flow rates are greater than 6 L/min [1] and may be up to 20 to 30 L/min [15,32], thus closer to 1 L/kg/min. FiO₂ is set to achieve target saturation between 92% and 97%. The gas temperature is set around 37°C in order to reach optimal humidification [33,34]. If the patient’s room is cool, it may be useful to insulate the tubing or to use breathing circuits with heating wires to limit condensation and the spray of water droplets into the child’s nostrils. If the phenomenon continues, the heater temperature can be reduced to a minimum of 34°C.

**The indications for HFNC**

Despite the advantages of this technique, the quality of the literature dealing with a pediatric population remains poor. The Cochrane Library deemed that no study was able to provide indications and guidelines for HFNC therapy in pediatric patients with a high level of evidence [2]. Similar conclusions were expressed about the use of HFNC in the specific situation of infants with acute viral bronchiolitis [35]. In 2014, recommendations are still based on extrapolations from observational or physiological studies, but not on evidence. For clinical practice, HFNC seems feasible in most of the populations currently managed with NIV, and sometimes, it appears to be better tolerated.

The most prudent course would be to restrict HFNC therapy to mild forms of respiratory distress and situations of discomfort or interface intolerance. Whatever the etiology of the respiratory distress, observational studies suggest significant success rates [15,26,27,36-38]. However, HFNC use in about 490 children with respiratory distress (bronchiolitis,
pneumonia or asthma) was associated with NIV failure and recourse to mechanical ventilation in 8% of the cases [29]. Unsurprisingly, the failures were observed in the most severely ill patients who presented with significant respiratory acidosis and remained tachypneic after initiation.

**Acute viral bronchiolitis**

HFNC has most often been evaluated in populations with acute viral bronchiolitis, with several studies comparing the efficacy and tolerance of HFNC with different CPAP systems [4,26,35,39].

Clinically, these infants show signs of severe obstructive lung disease, with a marked increase in respiratory resistance and reduced dynamic compliance. The ‘trapping’ phenomenon is exacerbated by the change in ventilatory pattern, being characterized by rises in the respiratory rate and in the ratio of inspiratory time (Ti) over the total respiratory cycle time (Ti/Ttot ratio) [40]. The gradual increase in end-expiratory volume generates a positive end-expiratory pressure or auto-PEEP. The work of breathing is increased because, at each inspiration, patients need to use their muscles to offset the auto-PEEP and then continue the work for generating an inspiratory flow despite the increased airways resistance.

Measurement of esophageal pressure helps to quantify the inspiratory effort required to ensure alveolar ventilation in this situation. The effort is about six times higher in infants with severe bronchiolitis than that observed in healthy infants [40]. Applying oropharyngeal pressure equivalent to the auto-PEEP generates an inspiratory flow as soon as the inspiratory muscles begin working and thus reduces the inspiratory burden [3,6,40,41]. In addition, CPAP may keep small airways open by enlarging the diameter (‘stenting’ effect), which in turn would reduce respiratory system resistance.

Several ‘before-after’ observational studies have suggested the interest of HFNC on both physiological [3,6] and clinical grounds [5,28,36-39], including a decreased rate of intubation as compared with historical controls prior to HFNC [26,27]. From this perspective, a failure rate comparable to that of CPAP performed with a nasopharyngeal tube was reported [4], while a recent randomized control study reported efficiency comparable to hypertonic saline [42]. However, no study to date has provided a direct demonstration of the risk of mechanical ventilation requirement as most of the patients included in these studies were not affected by severe forms of bronchiolitis. Therefore, it seems reasonable to reserve NIV/CPAP for severe bronchiolitis and to limit HFNC use to moderate forms of the disease.

**Withdrawal of invasive ventilation**

In the neonatal population, weaning from invasive ventilation is one of the main indications for HFNC, with recent randomized studies demonstrating efficiency comparable to that of CPAP [43,44]. In the adult population, as well, a few studies have suggested the advantages of using HFNC for this indication, but the number of patients is still modest [45]. These results need to be confirmed in larger populations [46]. In infants younger than 18 months, a recent randomized controlled trial compared HFNC to conventional oxygen therapy in the 48-h post-extubation after cardiac surgery [47]. HFNC had no influence on PaCO₂ values, which was the primary objective. However, its use appeared safe and improved PaO₂ in these patients. This pioneering work, along with the positive experience reported in this area with newborn and adult patients, should encourage studies on HFNC use for the withdrawal of
invasive ventilation in infants and children. For the moment, application of HFNC in this context is based only on the clinical judgment of the practitioner and initiated with great caution.

**Asthma**

From a physiological point of view, HFNC for asthmatic patients seems attractive. As in bronchiolitis, CPAP may reduce the burden on the inspiratory muscles related to auto-PEEP. Use of heated and humidified gas also limits the bronchoconstriction induced by cold dry gas. Theoretically, the high gas flow should improve the distribution of inhaled treatments. However, this effect remains a subject of controversy, as the dose of bronchodilator received varies from 0.5% to 25% of the administered dose [48,49]. Distal bronchodilator delivery might be improved by positioning the aerosol upstream of the humidifier, choosing an ultrasonic nebulizer over a pneumatic nebulizer or even using heliox gas as the vector [50,51]. However, the literature is scant on the use of high flow in this indication. Kelly et al. described the largest observational study to date, which included 38 children under 2 years of age presenting with a severe asthmatic attack [29]. Experience with HFNC for this indication is particularly lacking and this must be emphasized. For instance, in our PICU, we limit HFNC use to the mildest asthmatic attacks. Use of another type of NIV becomes mandatory if tachypnea and/or signs of respiratory distress do not improve within 1 h of HFNC initiation.

**Conclusions**

HFNC use is increasing in pediatric wards, despite the lack of clearly established benefits in the medical literature. The indication most cited in the publications is moderately severe bronchiolitis in infants, but recent reports suggest HFNC may also be effectively and safely applied to a broader spectrum of patient ages and diagnoses [29,37,38]. The system is very attractive because of its simplicity and excellent tolerance. On a practical level, this treatment should be initiated in the emergency department or the pediatric ICU in order to evaluate its effectiveness and identify as early as possible the signs of failure requiring a more appropriate respiratory support system.

**Competing interests**

Dr. Milesi received support from Fisher and Paekel to cover his travel costs and registration fees for the 2014 Congress of the Société de Réanimation de Langue Française. Doctors Boubal, Jacquot, Baleine, Durand, Pons, and Cambonie have no conflict of interest to declare.

**Authors’ contributions**

CM, MPO, and GC drafted the manuscript. MB, AJ, JFB, and SD critically reviewed the manuscript. All authors read and approved the final manuscript.
References

1. Lee JH, Rehder KJ, Williford L, Cheifetz IM, Turner DA: Use of high flow nasal cannula in critically ill infants, children, and adults: a critical review of the literature. *Intensive Care Med* 2013, 39:247–257.

2. Mayfield S, Jauncey-Cooke J, Hough JL, Schibler A, Gibbons K, Bogossian F: High-flow nasal cannula therapy for respiratory support in children. *Cochrane Database Syst Rev* 2014, 3, CD009850.

3. Milési C, Baleine J, Matecki S, Durand S, Combes C, Novais AR, Cambonie G: Is treatment with a high flow nasal cannula effective in acute viral bronchiolitis? A physiologic study. *Intensive Care Med* 2013, 39:1088–1094.

4. ten Brink F, Duke T, Evans J: High-flow nasal prong oxygen therapy or nasopharyngeal continuous positive airway pressure for children with moderate-to-severe respiratory distress? *Pediatr Crit Care Med* 2013, 14:e326–331.

5. Mayfield S, Bogossian F, O’Malley L, Schibler A: High-flow nasal cannula oxygen therapy for infants with bronchiolitis: pilot study. *J Paediatr Child Health* 2014, 50:373–378.

6. Pham TM, O’Malley L, Mayfield S, Martin S, Schibler A: The effect of high flow nasal cannula therapy on the work of breathing in infants with bronchiolitis. *Pediart Pulmonol* 2014. doi:10.1002/ppul.23060.

7. Roca O, Riera J, Torres F, Masclans JR: High-flow oxygen therapy in acute respiratory failure. *Respir Care* 2010, 55:408–413.

8. Hasani A, Chapman TH, McCool D, Smith RE, Dilworth JP, Agnew JE: Domiciliary humidification improves lung mucociliary clearance in patients with bronchiectasis. *Chron Respir Dis* 2008, 5:81–86.

9. Rea H, McAuley S, Jayaram L, Garrett J, Hockey H, Storey L, O’Donnell G, Haru L, Payton M, O’Donnell K: The clinical utility of long-term humidification therapy in chronic airway disease. *Respir Med* 2010, 104:525–533.

10. Fontanari P, Burnet H, Zattara-Hartmann MC, Jammes Y: Changes in airway resistance induced by nasal inhalation of cold dry, dry, or moist air in normal individuals. *J Appl Physiol* 1996, 81:1739–1743.

11. Tiep B, Barnett M: High flow nasal vs high flow mask oxygen delivery: tracheal gas concentrations through a head extention airway model [abstract]. *Respir Care* 2002, 47:1079.

12. Parke RL, McGuinness SP, Eccleston ML: A preliminary randomized controlled trial to assess effectiveness of nasal high-flow oxygen in intensive care patients. *Respir Care* 2011, 56:265–270.
13. Numa AH, Newth CJ: Anatomic dead space in infants and children. J Appl Physiol 1996, 80:1485–1489.

14. Dysart K, Miller T, Wolfson M, Marla R, Shaffer TH: Research in high flow therapy: mechanisms of action. Respir Med 2009, 103:1400–1405.

15. Spentzas T, Minarik M, Patters AB, Vinson B, Stidham G: Children with respiratory distress treated with high-flow nasal cannula. J Intensive Care Med 2009, 24:323–328.

16. Spence KL, Murphy D, Kilian C, Mc Gonigle R, Kilani RA: High-flow nasal cannula as a device to provide continuous positive airway pressure in infants. J Perinatol 2007, 27:772–775.

17. Wilkinson D, Andersen C, Smith K, Holberton J: Pharyngeal pressure with high-flow nasal cannulae in premature infants. J Perinatol 2007, 27:772–775.

18. Dani C, Pratesi S, Migliori C, Bertini G: High flow nasal cannula therapy as respiratory support in the preterm infant. Pediatr Pulmonol 2009, 44:629–634.

19. Teague WG: Noninvasive ventilation in the pediatric intensive care unit for children with acute respiratory failure. Pediatr Pulmonol 2003, 35:418–426.

20. Rubin S, Ghuman A, Deakers T, Khemani R, Ross P, Newth CJ: Effort of breathing in children receiving high-flow nasal cannula. Pediatr Crit Care Med 2014, 15:1–6.

21. Collins CL, Holberton JR, Barfield C, Davis PG: A randomized controlled trial to compare heated humidified high-flow nasal cannulae with nasal continuous positive airway pressure postextubation in premature infants. J Pediatr 2013, 162:949–954.

22. König K, Stock EL, Jarvis M: Noise levels of neonatal high-flow nasal cannula devices - an in-vitro study. Neonatology 2013, 103:264–267.

23. Hegde S, Prodhan P: Serious air leak syndrome complicating high-flow nasal cannula therapy: a report of 3 cases. Pediatrics 2013, 131:e939–44.

24. Sivieri EM, Gerdes JS, Abbasi S: Effect of HFNC flow rate, cannula size, and nares diameter on generated airway pressures: an in vitro study. Pediatr Pulmonol 2013, 48:506–514.

25. Carrillo A, Gonzalez-Diaz G, Ferrer M, Martinez-Quintana ME, Lopez-Martinez A, Llamas N, Alcazar M, Torres A: Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. Intensive Care Med 2012, 38:458–466.

26. McKiernan C, Chua LC, Visintainer PF, Allen H: High flow nasal cannulae therapy in infants with bronchiolitis. J Pediatr 2010, 156:634–638.

27. Schibler A, Pham TM, Dunster KR, Foster K, Barlow A, Gibbons K, Hough JL: Reduced intubation rates for infants after introduction of high-flow nasal prong oxygen delivery. Intensive Care Med 2011, 37:847–852.
28. Abboud PA, Roth PJ, Skiles CL, Stolfi A, Rowin ME: Predictors of failure in infants with viral bronchiolitis treated with high-flow, high-humidity nasal cannula therapy. *Pediatr Crit Care Med* 2012, 13:e343–349.

29. Kelly GS, Simon HK, Sturm JJ: High-flow nasal cannula use in children with respiratory distress in the emergency department: predicting the need for subsequent intubation. *Pediatr Emerg Care* 2013, 29:888–892.

30. Essouri S, Chevret L, Durand P, Haas V, Fauroux B, Devictor D: Noninvasive positive pressure ventilation: five years of experience in a pediatric intensive care unit. *Pediatr Crit Care Med* 2006, 7:329–334.

31. Schlapbach LJ, Schaefer J, Brady AM, Mayfield S, Schibler A: High-flow nasal cannula (HFNC) support in interhospital transport of critically ill children. *Intensive Care Med* 2014, 40:592–599.

32. McGinley B, Halbower A, Schwartz AR, Smith PL, Patil SP, Schneider H: Effect of a high-flow open nasal cannula system on obstructive sleep apnoea in children. *Pediatrics* 2009, 124:179–188.

33. Chikata Y, Izawa M, Okuda N, Itagaki T, Nakataki E, Onodera M, Imanaka H, Nishimura M: Humidification performances of two high flow nasal cannula devices: a bench study. *Respir Care* 2013. PMID:24368861.

34. Campbell EJ, Baker MD, Crites-Silver P: Subjective effects of humidification of oxygen for delivery by nasal cannula. A prospective study. *Chest* 1988, 93:289–293.

35. Beggs S, Wong ZH, Kaul S, Ogden KJ, Walters JA: High-flow nasal cannula therapy for infants with bronchiolitis. *Cochrane Database Syst Rev* 2014, 1, CD009609.

36. Bressan S, Balzani M, Krauss B, Pettenazzo A, Zanconato S, Baraldi E: High-flow nasal cannula oxygen for bronchiolitis in a pediatric ward: a pilot study. *Eur J Pediatr* 2013, 172:1649–1656.

37. Mayfield S, Jauncey-Cooke J, Bogossian F: A case series of paediatric high flow nasal cannula therapy. *Aust Crit Care* 2013, 26:189–192.

38. Wing R, James C, Maranda LS, Armsby CC: Use of high-flow nasal cannula support in the emergency department reduces the need for intubation in pediatric acute respiratory insufficiency. *Pediatr Emerg Care* 2012, 28:1117–1123.

39. Metge P, Grimaldi C, Hassid S, Thomachot L, Loundou A, Martin C, Michel F: Comparison of a high-flow humidified nasal cannula to nasal continuous positive airway pressure in children with acute bronchiolitis: experience in a pediatric intensive care unit. *Eur J Pediatr* 2014, 173:953–958.

40. Cambonie G, Milési C, Jaber S, Amsallem F, Barbotte E, Picaud JC, Matecki S: Nasal continuous positive airway pressure decreases respiratory muscles overload in young infants with severe acute viral bronchiolitis. *Intensive Care Med* 2008, 34:1865–1872.
41. Milési C, Matecki S, Jaber S, Mura T, Jacquot A, Pidoux O, Chautemps N, Novais AR, Combes C, Picaud JC, Cambonie G: 6 cmH\textsubscript{2}O continuous positive airway pressure versus conventional oxygen therapy in severe viral bronchiolitis: a randomized trial. *Pediatr Pulmonol* 2013, 48:45–51.

42. Bueno Campaña M, Olivares Ortiz J, Notario Muñoz C, Rupérez Lucas M, Fernández Rincón A, Patiño Hernández O, Calvo Rey C: High flow therapy versus hypertonic saline in bronchiolitis: randomised controlled trial. *Arch Dis Child* 2014, 99:511–515.

43. Manley BJ, Owen LS, Doyle LW, Andersen CC, Cartwright DW, Pritchard MA, Donath SM, Davis PG: High-flow nasal cannulae in very preterm infants after extubation. *N Engl J Med* 2013, 369:1425–1433.

44. Yoder BA, Stoddard RA, Li M, King J, Dirnberger DR, Abbasi S: Heated, humidified high-flow nasal cannula versus nasal CPAP for respiratory support in neonates. *Pediatrics* 2013, 131:e1482–1490.

45. Rittayamai N, Tscheikuna J, Rujiwit P: High-flow nasal cannula versus conventional oxygen therapy after endotracheal extubation: a randomized crossover physiologic study. *Respir Care* 2014, 59:485–490.

46. Futier E, Paugam-Burtz C, Constantin JM, Pereira B, Jaber S: The OPERA trial - comparison of early nasal high flow oxygen therapy with standard care for prevention of postoperative hypoxemia after abdominal surgery: study protocol for a multicenter randomized controlled trial. *Trials* 2013, 14:341.

47. Testa G, Iodice F, Ricci Z, Vitale V, De Razza F, Haiberger R, Iacoella C, Conti G, Cogo P: Comparative evaluation of high-flow nasal cannula and conventional oxygen therapy in paediatric cardiac surgical patients: a randomized controlled trial. *Interact Cardiovasc Thorac Surg* 2014. PMID:24912486.

48. Bhashyam AR, Wolf MT, Marcinkowski AL, Saville A, Thomas K, Carcillo JA, Corcoran TE: Aerosol delivery through nasal cannulas: an in vitro study. *J Aerosol Med Pulm Drug Deliv* 2008, 21:181–188.

49. Perry SA, Kesser KC, Geller DE, Selhorst DM, Rendle JK, Hertzog JH: Influences of cannula size and flow rate on aerosol drug delivery through the Vapotherm humidified high-flow nasal cannula system. *Pediatr Crit Care Med* 2013, 14:e250–256.

50. Ari A, Harwood R, Sheard M, Dailey P, Fink JB: In vitro comparison of heliox and oxygen in aerosol drug delivery using pediatric high flow nasal cannula. *Pediatr Pulmonol* 2011, 46:795–801.

51. Ari A, Atalay OT, Harwood R, Sheard MM, Aljamhan EA, Fink JB: Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. *Respir Care* 2010, 55:845–851.
### Patient selection

| Condition                                      | Recommendation |
|------------------------------------------------|----------------|
| Moderately severe bronchiolitis                | Yes            |
| Respiratory distress type 1 (atelectasis,      | Maybe          |
| pulmonary edema, pneumonia)                   |                |
| Moderate asthma                                | Maybe          |
| Invasive ventilation weaning                   | Maybe          |

### Settings

- Nasal cannula size: ½ nostril diameter
- Humidification: 34-37°C
- FiO₂: to reach pulse oximetry (SpO₂) 92-97%
- Flow rates:
  - Infants >2 L/min (i.e., 2 L/kg/min)
  - Children >6 L/min (i.e., 1 L/kg/min)

### Monitoring in PED or PICU

- Consciousness
- Airway patency
- Respiratory rate (RR), chest rising, FiO₂ and SpO₂
- Heart rate (HR), blood pressure
- Comfort

### Success

- Improvement in most parameters: particularly RR, FiO₂, HR, comfort

  After 12 hours:
  - Possible transfer to a pediatric ward depending on the hospital policy

### Failure

- Worsening of some parameters: particularly RR, FiO₂, HR, comfort

  Keep or transfer to PICU
  Change to NIV or invasive ventilation